← Leaderboards
Weixin Tang
University Of Chicago
$783,510
Attributed
$1,337,010
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $492K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,337,010 · 3
By mechanism
R21$1,107,000 · 2
R61$230,010 · 1
Top collaborators
- Jueqi Chen3 shared
- Jingyi Fei2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Chuan He$53,119,947
- Xiaoyang Wu$5,862,035
- Anna Di Rienzo$12,488,198
- Louis C Dore$139,136
- Jueqi Chen$2,213,652
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesDesignGenerationsBaseNucleaseComplexInterestCellsGuide RnaTranscriptMediatingPathway InteractionsTumorClinical OncologySpecificityMalignant NeoplasmsCell TypeLeadClinical TrialsAnti-CancerClustered Regularly Interspaced Short Palindromic RepeatsAnimal ModelAgonistCoculture Techniques
Grant awards (6)
Enriching and Base-Resolution Profiling of 5-Methylcytosine in Degraded Clinical Samples$230,010
R61 · FY2025 · CA · contact PI
An Engineered CRISPR System for Boosting Tumor Immunogenicity.$164,000
R21 · FY2023 · EB · contact PI
An Engineered CRISPR System for Boosting Tumor Immunogenicity.$246,000
R21 · FY2022 · EB · contact PI
Spatially resolved high throughput lineage tracing by targeted in situ DNA diversification$205,000
R21 · FY2022 · GM
Spatially resolved high throughput lineage tracing by targeted in situ DNA diversification$246,000
R21 · FY2021 · GM
An Engineered CRISPR System for Boosting Tumor Immunogenicity.$246,000
R21 · FY2021 · EB · contact PI